You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.
Latest BOOST Study Articles
Popular BOOST Study Articles
Highly Recommended BOOST Study Articles
Send a link to this page to your friends and colleagues.
Novo Nordisk's insulin degludec is injected once daily.
A brand new insulin will soon be on pharmacy shelves in the United States if Danish pharmaceutical company Novo Nordisk has its way. The company has filed for approval from the Food and Drug Administration to sell insulin degludec, an original formulation that lasts an extra-long time.
Insulin degludec is injected only once a day. Once under the skin, the dose of insulin is absorbed slowly and consistently, allowing for better nighttime control, according to Novo. Most importantly, test subjects had a low rate of hypoglycemia on the drug.
"We are very excited about being able to file for the approval of insulin degludec and insulin degludec/insulin aspart now also in the US," said Novo Executive Vice President and Chief Science Officer Mads Krogsgaard Thomsen. "This is another significant milestone for Novo Nordisk and for the millions of people with diabetes who require insulin."
As Thomsen mentioned, the company is also applying for approval of a dual formulation of insulin degludec and insulin aspart. In this combination, the long-lasting degludec is accompanied by the short-term aspart. An injection would therefore offer both 24-hour control and a needed bolus after a meal.
Extensive clinical trials have been undertaken to test the safety and efficacy of insulin degludec. The BEGIN and BOOST studies, which wrapped up last year, included nearly 10,000 people with type 1 or type 2 diabetes. Results from the studies showed that the insulin was indeed effective as a 24-hour treatment.
Novo Nordisk, which has a global reach, has spent nearly 90 years in the diabetes care field. Some of its best-known products include Levemir and NovoLog. Novo has also branched into hemophilia care, hormone replacement therapy, and growth hormone therapy.
Source:
http://press.novonordisk-us.com/index.php?s=43&item=304
Categories: BEGIN Study, BOOST Study, Diabetes, Diabetes, Food, Hypoglycemia, Injection, Insulin, Insulin Aspart, Insulin Degludec, Novo Nordisk, Type 2 Issues
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.

Comments
Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.
When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.
For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.
Don't have your Diabetes Health Username? Register now and add your comments to all our content.
Register...
Register your Diabetes Health Username here.
Have Your Say...